Physical compatibility and chemical stability of amikacin sulfate in combination with antibiotics in large-volume parenteral solutions - part III.
D000583:Amikacin / Q000032:analysis; D000666:Amphotericin B / Q000032:analysis; D000900:Anti-Bacterial Agents / Q000032:analysis; D002511:Cephalosporins / Q000032:analysis; D002701:Chloramphenicol / Q000032:analysis; D004338:Drug Combinations; D004344:Drug Incompatibility; D004355:Drug Stability; D004917:Erythromycin / Q000032:analysis; D007275:Injections, Intravenous; D007612:Kanamycin / Q000031:analogs & derivatives; D008034:Lincomycin / Q000032:analysis; D009675:Novobiocin / Q000032:analysis; D010406:Penicillins / Q000032:analysis; D011113:Polymyxins / Q000032:analysis; D012996:Solutions; D013754:Tetracyclines / Q000032:analysis; D013997:Time Factors; D014640:Vancomycin / Q000032:analysis
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; D010406:Penicillins; D011113:Polymyxins; D012996:Solutions; D013754:Tetracyclines; D009675:Novobiocin; D007612:Kanamycin; D004917:Erythromycin; D002701:Chloramphenicol; D014640:Vancomycin; D000666:Amphotericin B; D000583:Amikacin; D008034:Lincomycin